

TANDEM DIABETES CARE INC
 Form 3
 November 13, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Allen Dick (Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC.,Â 11045 ROSELLE STREET (Street) SAN DIEGO,Â CAÂ 92121 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/13/2013	3. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)	5. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
--	--	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	687	I	See footnote <u>(1)</u>
Common Stock	223	I	See footnote <u>(2)</u>
Common Stock	223	I	See footnote <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: TANDEM DIABETES CARE INC - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	38,454	\$ 0	I	See footnote <u>(6)</u>
Series A Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	3,691	\$ 0	I	See footnote <u>(1)</u>
Series B Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	13,258	\$ 0	I	See footnote <u>(6)</u>
Series B Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	1,004	\$ 0	I	See footnote <u>(1)</u>
Series C Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	9,842	\$ 0	I	See footnote <u>(6)</u>
Series C Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	4,921	\$ 0	I	See footnote <u>(1)</u>
Series D Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	50,044	\$ 0	I	See footnote <u>(6)</u>
Series D Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	28,672	\$ 0	I	See footnote <u>(1)</u>
Series D Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	596	\$ 0	I	See footnote <u>(2)</u>
Series D Preferred Stock	Â <u>(4)</u>	Â <u>(5)</u>	Common Stock	596	\$ 0	I	See footnote <u>(3)</u>
Preferred Stock Warrant	Â <u>(7)</u>	08/31/2021	Common Stock <u>(8)</u>	22,727 <u>(8)</u>	\$ 4.4 <u>(8)</u>	I	See footnote <u>(6)</u>
Preferred Stock Warrant	Â <u>(7)</u>	08/31/2021	Common Stock <u>(9)</u>	4,545 <u>(9)</u>	\$ 4.4 <u>(9)</u>	I	See footnote <u>(1)</u>
Preferred Stock Warrant	Â <u>(7)</u>	05/25/2022	Common Stock <u>(10)</u>	9,999 <u>(10)</u>	\$ 4.4 <u>(10)</u>	I	See footnote <u>(6)</u>
Preferred Stock Warrant	Â <u>(7)</u>	07/03/2022	Common Stock <u>(11)</u>	2,272 <u>(11)</u>	\$ 4.4 <u>(11)</u>	I	See footnote <u>(1)</u>
Preferred Stock Warrant	Â <u>(7)</u>	07/17/2022	Common Stock <u>(12)</u>	13,851 <u>(12)</u>	\$ 4.4 <u>(12)</u>	I	See footnote <u>(6)</u>
Preferred Stock Warrant	Â <u>(7)</u>	08/21/2022	Series D Preferred Stock <u>(13)</u>	7 <u>(13)</u>	\$ 4.4 <u>(13)</u>	I	See footnote <u>(1)</u>
Stock Option <u>(14)</u>	Â <u>(15)</u>	Â <u>(16)</u>	Common Stock	16,710	\$ 1.11	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Allen Dick C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET SAN DIEGO, CA 92121	X			

Signatures

/s/ David B. Berger, Attorney-in-Fact for Dick P.
Allen

11/13/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities are held by Cornerstone Ventures. The Reporting Person is the managing partner of Cornerstone Ventures and may be deemed to have indirect beneficial ownership of such securities. The Reporting Person disclaims beneficial ownership of such securities held by Cornerstone Ventures, except to the extent of his proportionate pecuniary interest therein.
- (2) The securities are held by the Gammon Children's 2000 Trust FBO Hannah Lee Gammon. The Reporting Person is co-trustee of the Gammon Children's 2000 Trust FBO Hannah Lee Gammon and has shared voting and investment power over the securities held by the Gammon Children's 2000 Trust FBO Hannah Lee Gammon and may be deemed to have indirect beneficial ownership of such securities. The Reporting Person disclaims beneficial ownership of such securities held by the Gammon Children's 2000 Trust FBO Hannah Lee Gammon.
- (3) The securities are held by the Gammon Children's 2000 Trust FBO Jake Allen Gammon. The Reporting Person is co-trustee of the Gammon Children's 2000 Trust FBO Jake Allen Gammon and has shared voting and investment power over the securities held by the Gammon Children's 2000 Trust FBO Hannah Lee Gammon and may be deemed to have indirect beneficial ownership of such securities. The Reporting Person disclaims beneficial ownership of such securities held by the Gammon Children's 2000 Trust FBO Jake Allen Gammon.
- (4) The securities are immediately convertible.
- (5) The expiration date is not relevant to the conversion of these securities.
- (6) The securities are held by the Allen Family Trust dated 10/12/81.
- (7) The warrants are immediately exercisable.
- (8) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 13,563 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (9) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 2,712 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (10) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 5,967 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (11) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 1,355 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (12) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 8,266 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (13) Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 4 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- (14) Granted pursuant to the Issuer's Tandem Diabetes Care, Inc. 2006 Stock Incentive Plan.

Edgar Filing: TANDEM DIABETES CARE INC - Form 3

(15) The date of grant of the option was 4/23/2013. All shares subject to the option will vest in 24 equal monthly installments commencing on 4/23/2013.

(16) The expiration date of these options is 10 years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.